Solvias
Solvias AG is a Switzerland-based cGMP contract research organization providing CMC analytical services — including method development, release testing, stability, biosafety, extractables & leachables, and genetic QC via proprietary TLA technology — to 700+ pharmaceutical, biotech, and medical-device clients across 6 European and U.S. Centers of Excellence.
- Company typePrivate
- Founded1999
- HeadquartersKaiseraugst, Switzerland
- Headcount501–1,000
- GTM typeB2B
- OfferingServices
What Solvias does
Solvias AG is a Switzerland-headquartered contract research organization (CRO) spun out of Novartis in 1999, providing cGMP-compliant CMC (Chemistry, Manufacturing, and Controls) analytical services to the pharmaceutical, biotech, medical-device, and cosmetics industries. Its core technology stack spans chromatography (HPLC, UPLC, CE), mass spectrometry (LC-MS, GC-MS, HRAM), spectroscopy, molecular biology, and biosafety methods, complemented by the proprietary Targeted Locus Amplification (TLA) platform acquired with Cergentis in 2022. The service portfolio covers analytical method development and validation, drug substance and drug product release testing (with stated 10-15 day turnaround), extractables and leachables testing, biosafety, stability testing (600+ programs over 20+ years), container closure integrity testing, cell-based bioassays, impurity and nitrosamine testing, and genetic quality control for biologics and ATMPs (supported by ~3,800 GMP-compliant tests annually and released commercial support for 4 ATMPs and 2 biologics).
The business operates on a B2B professional-services model, selling fixed-price and time-and-materials analytical engagements to enterprise pharmaceutical and biotech clients via direct field sales, consultative subject-matter-expert engagement, and channels including CPHI conferences, white papers, and webinars. Solvias reports 700+ customers worldwide and 19 of the top 20 pharma companies as clients, delivered through 5-6 Centers of Excellence (Kaiseraugst CH headquarters, Hombourg FR, Utrecht NL, Canton MA, Morrisville NC RTP). Talent depth is a stated differentiator, with 175+ PhD-level scientists on an ~800-person base, and revenue is captured through project-based service fees for drug development phases spanning preclinical through commercial.
Ownership and capital structure center on JLL Partners, a middle-market private equity firm that invested through its $1.4 billion Fund IX (2026). Solvias executed three acquisitions over the past decade (Confarma 2013, Chemic 2021, Cergentis 2022), expanded U.S. capacity with a 2025 RTP Center of Excellence for Biologics & CGT, and rolled out a new ERP (2024) following a 2023 LIMS deployment. Regulatory positioning includes Swissmedic, ANSM, and FDA GMP certifications, ISO 17025/9001/14001/45001/26000, DEA licensing, MIA certification, and an EcoVadis Bronze Medal (2026).
Solvias firmographics
Firmographics- Name
- Solvias
- Legal name
- Solvias AG
- Website
- https://solvias.com
- Company type
- Private
- Founded year
- 1999
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Solvias AG is a Switzerland-based cGMP contract research organization providing CMC analytical services — including method development, release testing, stability, biosafety, extractables & leachables, and genetic QC via proprietary TLA technology — to 700+ pharmaceutical, biotech, and medical-device clients across 6 European and U.S. Centers of Excellence.
- Ownership category
- akta.pro rank
Solvias industry classification
Industry- Product category
- Pharmaceutical Analytical Testing & CMC Services
- NAICS
- Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)
- akta.pro primary industry
- Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)
- akta.pro secondary industry
- Clinical Quality Assurance (GCP QA, TMF/QMS oversight) (HLAGAKAI)
Keywords
Where Solvias is headquartered
LocationHeadquarters
- HQ city
- Kaiseraugst
- HQ country
- Switzerland
- HQ region
- Europe
Offices5 records
Markets served
Solvias business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- Contract Research and Testing Services: Solvias generates revenue through providing cGMP-compliant analytical testing, method development, validation, and release testing services on a project-by-project basis. Services are contracted for specific drug development phases from preclinical through commercial. Revenue is earned through service fees, typically structured as fixed-price projects or time-and-materials contracts with pharmaceutical and biotech clients.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels6 records
Solvias product offering
Product offeringCore offering
Solvias is a global cGMP contract research organization providing comprehensive CMC (Chemistry, Manufacturing, and Controls) analytical services for pharmaceutical, biotech, medical device, and cosmetics companies. The company delivers method development and validation, drug substance and drug product release testing, stability studies, extractables and leachables testing, biosafety testing, genetic quality control, cell-based bioassays, and impurity analysis across small molecules, biologics, and cell and gene therapies. Services are delivered through six Centers of Excellence in Switzerland, France, the Netherlands, and the United States, with proprietary Targeted Locus Amplification (TLA) technology supporting genetic characterization.
Product overview
Solvias is a global contract research organization (CRO) providing comprehensive CMC (Chemistry, Manufacturing, and Controls) analytics services. The company offers a unified platform of analytical testing and characterization services spanning the entire drug development journey from research through commercialization. The core portfolio includes Analytical Method Development & Validation, cGMP Drug Substance & Drug Product Testing & Release, Extractables & Leachables Testing, Biosafety Testing, Stability Testing, and Container Closure Integrity Testing (CCIT). The company also provides specialized services including Genetic Quality Control Testing powered by proprietary Targeted Locus Amplification (TLA) technology, Cell-Based Bioassays, and Impurity Testing & Contamination Control. For small molecules, Solvias offers API development and manufacturing capabilities alongside Process Analytical Technology (PAT) products including fiber optic probes. The service offering is delivered across six global Centers of Excellence in Switzerland, France, Netherlands, and the United States, with expertise covering biologics, cell & gene therapies, and small molecules.
Differentiator
Problem solved
Functional benefit
Brands
- Targeted Locus Amplification (TLA): Proprietary technology platform for genetic quality control, enabling complete and targeted gene sequencing for detection of single nucleotide variants and structural variants.
Products and services
- Analytical Method Development & Validation
- cGMP Drug Substance & Drug Product Testing & Release
- Analytical Characterization Services
- Extractables & Leachables Testing
- Stability Testing
- Biosafety Testing
- Impurity Testing & Contamination Control
- Container Closure Integrity Testing (CCIT) Deterministic and probabilistic CCIT solutions including vacuum decay, pressure decay, dye ingress, and microbial ingress testing aligned with USP <1207>, EU GMP Annex 1, and PDA Technical Report 27.
- Excipient & Raw Materials Testing and Release
- Cell-Based Bioassays
- Genetic Quality Control Testing
- Ligands & Catalysts
- Process Analytical Technology (PAT)
Quantifiable outcome
- 10-15 day turnaround for full panel drug substance and drug product release testing
- +4 more outcomes
Companies that use Solvias
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles3 records
Solvias technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Solvias partnerships and signals
Strategic signalScale indicators9 records
Recent moves9 records
Expansion highlights6 records
Solvias competitors and assessment
Company assessmentDirect peers
- Intertek Life Sciences: Global testing services provider with pharmaceutical services including analytical method development, stability, impurity and E&L testing. Directly comparable CMC analytical testing offering for the same regulated pharmaceutical customers.
- Eurofins Scientific: Global testing-services leader with deep pharmaceutical product testing, bioanalytical, and cosmetics practices. Directly competes with Solvias across CMC analytical testing, release testing, stability, extractables and leachables, and biosafety for pharma and biotech customers.
- WuXi AppTec: Global CRO/CDMO offering comprehensive analytical and CMC services including biologics testing and CGT characterization. Directly competitive with Solvias on small molecule, biologics, and cell and gene therapy analytical engagements.
- SGS Life Sciences: Major global testing services group with a sizeable pharmaceutical analytical services practice covering method development, validation, stability, and impurity testing. Directly comparable scope in CMC and quality control services for pharma and biotech.
Broad incumbents
- Syneos Health: Global clinical and bioanalytical CRO with biopharma services. Overlaps Solvias in pharmaceutical testing services as part of a clinical-development-oriented portfolio.
- Thermo Fisher Scientific (PPD): Global CRO through PPD plus bioanalytical and central lab services. Offers overlapping CMC testing for biologics and cell therapies within a much broader life sciences tools and services portfolio.
- ICON plc: Major global CRO with central lab and bioanalytical capabilities after the PRA Health Sciences acquisition. Competes in pharma testing services with a clinical-trial-tilted portfolio.
- IQVIA: Largest global CRO with R&D Solutions laboratory and bioanalytical services covering CMC and clinical testing. Competes with Solvias in pharma analytics as part of a much broader CRO and data services portfolio.
- Labcorp (Covance Drug Development): Global CRO via Covance plus central and biopharma lab services. Overlaps Solvias in CMC and bioanalytical work while also offering clinical trial laboratory and broader diagnostic testing.
- Charles River Laboratories: Large global CRO with Biologics Services, Cell & Gene Therapy, and Discovery/Safety operations. Overlaps Solvias in analytical testing, CGT characterization, and biosafety testing while also serving broader preclinical and manufacturing needs.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Solvias social profiles
Digital presenceSolvias compliance and trust
Trust signalCompliance11 records
Solvias financial estimates
Financial estimateRevenue estimate
Valuation estimate
Solvias leadership team
Management profileNumber of profiles
Profiles1 record
Solvias subsidiaries and ownership
Company hierarchySubsidiaries3 records
Solvias funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Solvias M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Solvias
What does Solvias do?
Solvias is a global cGMP contract research organization providing comprehensive CMC (Chemistry, Manufacturing, and Controls) analytical services for pharmaceutical, biotech, medical device, and cosmetics companies. The company delivers method development and validation, drug substance and drug product release testing, stability studies, extractables and leachables testing, biosafety testing, genetic quality control, cell-based bioassays, and impurity analysis across small molecules, biologics, and cell and gene therapies. Services are delivered through six Centers of Excellence in Switzerland, France, the Netherlands, and the United States, with proprietary Targeted Locus Amplification (TLA) technology supporting genetic characterization.
Is Solvias a public or private company?
Solvias is a private company. It is classified as private equity controlled and is currently operating.
When was Solvias founded?
Solvias was founded in 1999. It employs 501 to 1,000 people.
Where is Solvias based?
Solvias is headquartered in Kaiseraugst, Switzerland, in the Europe region.
How does Solvias make money?
One revenue line is on record: contract Research and Testing Services.
Who are Solvias's main competitors?
Direct peers on record are Intertek Life Sciences, Eurofins Scientific, WuXi AppTec and SGS Life Sciences. Broad incumbents are Syneos Health, Thermo Fisher Scientific (PPD), ICON plc, IQVIA, Labcorp (Covance Drug Development) and Charles River Laboratories.
Does Solvias have an API?
No public API is recorded for Solvias.
What industry is Solvias in?
Solvias's product category is Pharmaceutical Analytical Testing & CMC Services. Its primary akta.pro industry code is HLAGAHAM, Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC), with a secondary code of HLAGAKAI, Clinical Quality Assurance (GCP QA, TMF/QMS oversight). Its NAICS code is 5417 and its SIC code is 8731.